33.60
price up icon0.51%   0.17
after-market Dopo l'orario di chiusura: 33.74 0.14 +0.42%
loading
Precedente Chiudi:
$33.43
Aprire:
$33.135
Volume 24 ore:
6.72M
Relative Volume:
1.17
Capitalizzazione di mercato:
$68.55B
Reddito:
$39.71B
Utile/perdita netta:
$3.17B
Rapporto P/E:
9.7609
EPS:
3.4423
Flusso di cassa netto:
$6.05B
1 W Prestazione:
-1.03%
1M Prestazione:
+0.75%
6M Prestazione:
-17.57%
1 anno Prestazione:
-7.16%
Intervallo 1D:
Value
$33.04
$33.87
Intervallo di 1 settimana:
Value
$33.04
$34.55
Portata 52W:
Value
$32.83
$45.92

Gsk Plc Adr Stock (GSK) Company Profile

Name
Nome
Gsk Plc Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
70,200
Name
Cinguettio
@GSK
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
GSK's Discussions on Twitter

Confronta GSK con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
GSK
Gsk Plc Adr
33.60 68.55B 39.71B 3.17B 6.05B 1.5382
Drug Manufacturers - General icon
LLY
Lilly Eli Co
767.76 690.46B 40.86B 8.37B -2.28B 9.25
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
85.00 377.54B 39.36B 13.79B 9.83B 3.086
Drug Manufacturers - General icon
JNJ
Johnson Johnson
144.47 347.83B 87.70B 14.68B 19.03B 6.05
Drug Manufacturers - General icon
ABBV
Abbvie Inc
175.58 310.27B 55.53B 5.12B 15.62B 2.88
Drug Manufacturers - General icon
MRK
Merck Co Inc
98.05 248.03B 63.17B 12.15B 14.84B 4.77

Gsk Plc Adr Stock (GSK) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-15 Downgrade Deutsche Bank Buy → Hold
2024-11-12 Downgrade Jefferies Buy → Hold
2024-10-31 Downgrade Guggenheim Buy → Neutral
2024-07-08 Downgrade UBS Buy → Neutral
2024-05-30 Iniziato Goldman Neutral
2024-03-04 Aggiornamento Guggenheim Neutral → Buy
2024-02-13 Aggiornamento Citigroup Neutral → Buy
2024-01-23 Iniziato Morgan Stanley Equal-Weight
2024-01-16 Ripresa UBS Buy
2024-01-03 Aggiornamento Jefferies Hold → Buy
2023-07-14 Iniziato HSBC Securities Reduce
2023-03-17 Aggiornamento Deutsche Bank Hold → Buy
2023-02-27 Ripresa Goldman Buy
2023-01-03 Downgrade JP Morgan Neutral → Underweight
2022-12-05 Downgrade BofA Securities Neutral → Underperform
2022-11-11 Downgrade UBS Neutral → Sell
2022-09-15 Aggiornamento Credit Suisse Underperform → Neutral
2022-09-08 Downgrade Jefferies Buy → Hold
2022-08-05 Ripresa Morgan Stanley Equal-Weight
2022-07-21 Ripresa Citigroup Neutral
2022-02-11 Downgrade DZ Bank Buy → Hold
2021-11-05 Aggiornamento Barclays Underweight → Equal Weight
2021-06-24 Aggiornamento Deutsche Bank Sell → Hold
2021-03-23 Downgrade SVB Leerink Outperform → Mkt Perform
2021-02-04 Downgrade Deutsche Bank Hold → Sell
2021-01-20 Downgrade Credit Suisse Neutral → Underperform
2021-01-15 Iniziato Deutsche Bank Hold
2020-11-02 Aggiornamento Liberum Hold → Buy
2020-09-29 Iniziato Berenberg Buy
2020-02-12 Downgrade Shore Capital Hold → Sell
2020-01-16 Downgrade Barclays Equal Weight → Underweight
2019-12-02 Iniziato SVB Leerink Outperform
2019-11-21 Aggiornamento UBS Neutral → Buy
2019-10-11 Aggiornamento Cantor Fitzgerald Hold → Buy
2019-09-03 Ripresa Citigroup Neutral
2019-09-03 Aggiornamento Societe Generale Sell → Buy
2019-08-13 Ripresa JP Morgan Neutral
2019-06-17 Ripresa Morgan Stanley Underweight
2019-03-08 Downgrade Shore Capital Buy → Hold
2019-02-22 Downgrade UBS Buy → Neutral
2019-01-14 Downgrade Exane BNP Paribas Outperform → Neutral
2018-12-11 Ripresa Jefferies Buy
2018-10-09 Iniziato Guggenheim Neutral
2018-08-30 Downgrade Liberum Buy → Hold
2018-04-04 Aggiornamento Exane BNP Paribas Neutral → Outperform
2018-03-22 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2018-02-09 Aggiornamento Kepler Reduce → Hold
Mostra tutto

Gsk Plc Adr Borsa (GSK) Ultime notizie

pulisher
Dec 12, 2024

FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - MSN

Dec 12, 2024
pulisher
Dec 11, 2024

GSK Stock Declines 20% In 3 Months: Should You Buy, Sell Or Hold? - Barchart

Dec 11, 2024
pulisher
Dec 11, 2024

GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold? - Zacks Investment Research

Dec 11, 2024
pulisher
Dec 10, 2024

GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex - Benzinga

Dec 10, 2024
pulisher
Dec 09, 2024

FDA Accepts GSK's Filing For Expanded Use Of Nucala In COPD - Barchart

Dec 09, 2024
pulisher
Dec 06, 2024

GSK Expands Vaccine Collaboration With Zhifei in China - MSN

Dec 06, 2024
pulisher
Dec 02, 2024

GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US - MSN

Dec 02, 2024
pulisher
Dec 02, 2024

The 10 Best US Companies to Invest in Now - Morningstar

Dec 02, 2024
pulisher
Nov 28, 2024

GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo - Zacks Investment Research

Nov 28, 2024
pulisher
Nov 22, 2024

10 Best Value Stocks to Buy for the Long Term - Morningstar

Nov 22, 2024
pulisher
Nov 18, 2024

5 Stocks to Buy While They’re Still Cheap After Earnings - Morningstar

Nov 18, 2024
pulisher
Nov 13, 2024

Diabetes Care Nutrition Market Report 2024 with Forecasts to 2029 - GlobeNewswire Inc.

Nov 13, 2024
pulisher
Nov 04, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Nov 04, 2024
pulisher
Nov 04, 2024

The Best Defensive Stocks to Buy - Morningstar

Nov 04, 2024
pulisher
Nov 01, 2024

GSK Plc ADR (NYSE: GSK) Has Outstanding Potential - Stocks Register

Nov 01, 2024
pulisher
Oct 30, 2024

GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

What Do Analysts Think About ICICI Bank Ltd. ADR’s (NYSE:IBN) Future? - Stocks Register

Oct 29, 2024
pulisher
Oct 25, 2024

GSK Plc ADR (GSK): An Important Analyst Insights - Stocks Register

Oct 25, 2024
pulisher
Oct 21, 2024

5 Stocks to Buy if You’re Concerned About US Market Valuations - Morningstar

Oct 21, 2024
pulisher
Oct 18, 2024

21 Best Healthcare Companies to Invest In - Morningstar

Oct 18, 2024
pulisher
Oct 16, 2024

Current share price is - GSK

Oct 16, 2024
pulisher
Oct 15, 2024

D-Wave Quantum Inc (QBTS) rating initates by B. Riley Securities - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

GSK's Studies On Depemokimab For Nasal Polyps Meet Primary Goals - Barchart

Oct 15, 2024
pulisher
Oct 15, 2024

Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.

Oct 15, 2024
pulisher
Oct 15, 2024

GSK Plc ADR [GSK] is 5.59% higher this YTD. Is it still time to buy? - The DBT News

Oct 15, 2024
pulisher
Oct 14, 2024

What You Didn’t Know About General Motors Company (NYSE: GM) This Week - Stocks Register

Oct 14, 2024
pulisher
Oct 14, 2024

GSK’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Oct 14, 2024
pulisher
Oct 14, 2024

Before You Invest, Make Sure You Check This ADT Inc (NYSE: ADT) Analysis - Stocks Register

Oct 14, 2024
pulisher
Oct 14, 2024

What Are You Thinking About Investing In Medical Properties Trust Inc (NYSE: MPW) Stock? - Stocks Register

Oct 14, 2024
pulisher
Oct 10, 2024

Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday - sharewise

Oct 10, 2024
pulisher
Oct 10, 2024

Introducing Our Rant Against GSK Plc ADR - US Post News

Oct 10, 2024
pulisher
Oct 10, 2024

GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy - Zacks Investment Research

Oct 10, 2024
pulisher
Oct 09, 2024

Balance Sheet Insights: GSK Plc ADR (GSK)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Oct 09, 2024
pulisher
Oct 09, 2024

Pilgrim’s Pride Corp. (PPC) receives an Equal-weight rating from Stephens - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Berenberg upgrades Carnival plc ADR (CUK) stock to a Hold - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

JP Morgan analysts downgrades an Underweight rating for Organon & Co. (OGN) - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

GSK Plc ADR (GSK) gets rating Downgrade from UBS - Knox Daily

Oct 09, 2024
pulisher
Oct 08, 2024

GSK Plc ADR (GSK) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Oct 08, 2024

Gsk Plc Adr Azioni (GSK) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general BMY
$57.33
price up icon 1.83%
drug_manufacturers_general SNY
$47.71
price up icon 0.44%
$263.38
price up icon 0.84%
drug_manufacturers_general PFE
$26.36
price up icon 2.29%
drug_manufacturers_general NVS
$97.11
price up icon 0.35%
drug_manufacturers_general MRK
$98.05
price down icon 1.48%
Capitalizzazione:     |  Volume (24 ore):